A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate

Clinical Therapeutics

Volumn 23, Issue 9, 2001, Pages 1339-1354

  Crim, Courtney ^a   Pierre, Lisa N ^b   Daley Yates, Peter T ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Fluticasone propionate; Mometasone furoate; Structure activity relationship; Total systemic bioavailability

Indexed keywords

BUDESONIDE; CD28 ANTIGEN; CD4 ANTIGEN; CHLORAMPHENICOL ACETYLTRANSFERASE; DEXAMETHASONE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; HISTAMINE; HYDROCORTISONE; INTERLEUKIN 4; INTERLEUKIN 5; MOMETASONE FUROATE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ASTHMA; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; IMMUNOMODULATION; LIPOPHILICITY; PHYSICAL CHEMISTRY; POWDER INHALER; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034801464     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80113-2     Document Type: Article

References (45)

1. The human pharmacology of fluticasone propionate
2. Structure-activity relationships of topically active steroids: The selection of fluticasone propionate
3. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor
4. Mometasone furoate. A review of its intranasal use in allergic rhinitis
5. Structure-activity relationships of a series of novel topical corticosteroids
6. 17-Heteroaroyl esters of corticosteroids. 2.11β-Hydroxy series
7. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids
8. Treatment of seasonal allergic rhinitis with fluticasone propionate aqueous nasal spray: Review of comparator studies
9. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma
10. Diskus and Diskhaler: Efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma
11. Dose-ranging study of a new steroid for asthma: Mometasone furoate dry powder inhaler
12. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses
13. Inhaled glucocorticoids for asthma
14. Bioavailability of orally administered micronized fluticasone propionate
15. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity
16. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant
17. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers
18. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers
19. The relative systemic exposure to fluticasone propionate and mometasone furoate administered as aqueous nasal sprays in healthy adults
20. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analog; inhibitors of the synthesis and actions of adenocortical hormones
21. Corticosteroids
22. Synthesis and structure-activity relationships in a series of antiinflammatory corticosteroid analogues, halomethyl androstane-17β-carbothioates and -17β-carboselenoates
23. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16α, 17αacetal-substituted glucocorticoids
24. Nature of steroid-glucocorticoid receptor interactions: Thermodynamic analysis of the binding reaction
25. A bioassay for the concomitant assessment of the antiphlogistic and thymolytic activities of topically applied corticoids
26. Method for comparing percutaneous absorption of steroids
27. Development of fluticasone propionate and comparison with other inhaled corticosteroids
28. Chromatographic hydrophobicity index by fast-gradient RP-HPLC: A high-throughput alternative to log P/log D
29. H)
30. The mechanism of action of corticosteroids in asthma
31. 2-adrenergic receptor transcription in human lung
32. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: Enhancer, TATA box, and RNA start site (Inr motif) occlusion
33. Anti-inflammatory actions of steroids: Molecular mechanisms
34. Pharmacodynamics Mechanism of action and relationship between drug concentration and effect
35. Transcriptional potencies of inhaled glucocorticoids
36. + T cells
37. An in vitro comparison of commonly used topical glucocorticoid preparations
38. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids
39. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma
40. Systemic bioavailability of inhaled steroids: The importance of appropriate and comparable methodology
41. The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild to moderate persistent asthma
42. Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue
43. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue
44. Budesonide. An updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis